187 related articles for article (PubMed ID: 31281204)
1. Innovation as a value in healthcare priority-setting: the UK experience.
Charlton V; Rid A
Soc Justice Res; 2019; 32(2):208-238. PubMed ID: 31281204
[TBL] [Abstract][Full Text] [Related]
2. Justice, Transparency and the Guiding Principles of the UK's National Institute for Health and Care Excellence.
Charlton V
Health Care Anal; 2022 Jun; 30(2):115-145. PubMed ID: 34750743
[TBL] [Abstract][Full Text] [Related]
3. NICE and Fair? Health Technology Assessment Policy Under the UK's National Institute for Health and Care Excellence, 1999-2018.
Charlton V
Health Care Anal; 2020 Sep; 28(3):193-227. PubMed ID: 31325000
[TBL] [Abstract][Full Text] [Related]
4. Modifying NICE's Approach to Equity Weighting.
Paulden M; McCabe C
Pharmacoeconomics; 2021 Feb; 39(2):147-160. PubMed ID: 33517512
[TBL] [Abstract][Full Text] [Related]
5. An empirical ethics study of the coherence of NICE technology appraisal policy and its implications for moral justification.
Charlton V; DiStefano M
BMC Med Ethics; 2024 Mar; 25(1):28. PubMed ID: 38448909
[TBL] [Abstract][Full Text] [Related]
6. Does NICE apply the rule of rescue in its approach to highly specialised technologies?
Charlton V
J Med Ethics; 2022 Feb; 48(2):118-125. PubMed ID: 33685978
[TBL] [Abstract][Full Text] [Related]
7. Public Reasoning and Health-Care Priority Setting: The Case of NICE.
Rumbold B; Weale A; Rid A; Wilson J; Littlejohns P
Kennedy Inst Ethics J; 2017; 27(1):107-134. PubMed ID: 28366905
[TBL] [Abstract][Full Text] [Related]
8. NICE's social value judgements about equity in health and health care.
Shah KK; Cookson R; Culyer AJ; Littlejohns P
Health Econ Policy Law; 2013 Apr; 8(2):145-65. PubMed ID: 22717361
[TBL] [Abstract][Full Text] [Related]
9. Some inconsistencies in NICE's consideration of social values.
Paulden M; O'Mahony JF; Culyer AJ; McCabe C
Pharmacoeconomics; 2014 Nov; 32(11):1043-53. PubMed ID: 25145802
[TBL] [Abstract][Full Text] [Related]
10. The normative grounds for NICE decision-making: a narrative cross-disciplinary review of empirical studies.
Charlton V
Health Econ Policy Law; 2022 Oct; 17(4):444-470. PubMed ID: 35293306
[TBL] [Abstract][Full Text] [Related]
11. Exorcising the positivist ghost in the priority-setting machine: NICE and the demise of the 'social value judgement'.
Charlton V; Weale A
Health Econ Policy Law; 2021 Oct; 16(4):505-511. PubMed ID: 33568251
[TBL] [Abstract][Full Text] [Related]
12. Views of Directors of Public Health about NICE Appraisal Guidance: results of a postal survey. National Institute for Clinical Excellence.
Davies E; Littlejohns P
J Public Health Med; 2002 Dec; 24(4):319-25. PubMed ID: 12546211
[TBL] [Abstract][Full Text] [Related]
13. The cancer technology appraisal programme of the UK's National Institute for Clinical Excellence.
Littlejohns P; Barnett D; Longson C;
Lancet Oncol; 2003 Apr; 4(4):242-50. PubMed ID: 12681268
[TBL] [Abstract][Full Text] [Related]
14. The NICE cost-effectiveness threshold: what it is and what that means.
McCabe C; Claxton K; Culyer AJ
Pharmacoeconomics; 2008; 26(9):733-44. PubMed ID: 18767894
[TBL] [Abstract][Full Text] [Related]
15. Are the UK systems of innovation and evaluation of medical devices compatible? The role of NICE's Medical Technologies Evaluation Programme (MTEP).
Chapman AM; Taylor CA; Girling AJ
Appl Health Econ Health Policy; 2014 Aug; 12(4):347-57. PubMed ID: 24934924
[TBL] [Abstract][Full Text] [Related]
16. DECISION-COMPONENTS OF NICE'S TECHNOLOGY APPRAISALS ASSESSMENT FRAMEWORK.
de Folter J; Trusheim M; Jonsson P; Garner S
Int J Technol Assess Health Care; 2018 Jan; 34(2):163-171. PubMed ID: 29633673
[TBL] [Abstract][Full Text] [Related]
17. Cost Effectiveness of Durvalumab in Unresectable Stage III NSCLC: 4-Year Survival Update and Model Validation from a UK Healthcare Perspective.
Dunlop W; van Keep M; Elroy P; Perez ID; Ouwens MJNM; Sarbajna T; Zhang Y; Greystoke A
Pharmacoecon Open; 2022 Mar; 6(2):241-252. PubMed ID: 34532842
[TBL] [Abstract][Full Text] [Related]
18. Financial interests of patient organisations contributing to technology assessment at England's National Institute for Health and Care Excellence: policy review.
Mandeville KL; Barker R; Packham A; Sowerby C; Yarrow K; Patrick H
BMJ; 2019 Jan; 364():k5300. PubMed ID: 30651227
[TBL] [Abstract][Full Text] [Related]
19. The use of cost-effectiveness by the National Institute for Health and Clinical Excellence (NICE): no(t yet an) exemplar of a deliberative process.
Schlander M
J Med Ethics; 2008 Jul; 34(7):534-9. PubMed ID: 18591289
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
